• 1.

    Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE 9; 1: e84943.

  • 2.

    Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23:16311634.

  • 3.

    Zhong H, et al.. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease. Drug Design, Development and Therapy 2018; 12:30033011.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Hasegawa A, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Curr Opin Nephrol Hypertens 27; 5:331338.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Kular D, Macdougall IC. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatric Nephrology 34; 3:36578.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Macdougall IC, et al.. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol 2019; 14:2839.

  • 7.

    Akizawa T, et al.. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol 2019; 49:271280.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Macdougall IC, et al.. Incidence of erythropoietin-mediated pure red cell aplasia: the prospective immunogenicity surveillance registry (PRIMS). Nephrol Dial Transplant 2015; 30:451460.

    • Crossref
    • Search Google Scholar
    • Export Citation

Hypoxia-Inducible Factor Stabilizers for Treating Anemia of CKD

  • 1 Edgar V. Lerma, MD, is clinical professor of medicine in the nephrology section at the University of Illinois at Chicago College of Medicine in Oak Lawn, IL. He is a member of the Kidney News Editorial Board.
Restricted access
Save